29 September 2026

Argent BioPharma Signs NLC Licence to Expand Antiviral Portfolio

Highlights:

- **Exclusive, royalty-bearing licence to commercialise the antiviral applications addressed by NLC's Tollovir, Tollovid and NutraVir, including related formulations, data, trade secrets and know-how.**
- **Portfolio complements Argent's immune-modulation and anti-inflammatory focus alongside CimetrA®.**
- **Licence territory extends worldwide excluding China, with existing TolloHealth rights in the United States preserved.**
- **Commercial structure combines monthly licence fees, tiered sales royalties and cash and equity consideration linked to sales milestones.**

Argent BioPharma Ltd (Argent or the Company) announces that it has entered into a licence agreement with NLC Ltd., NLC Viral Defense, LLC (together, NLC) and Dr. Dorit Arad for the commercialisation of the Licensed Products identified in Schedule A.

The agreement expands Argent's portfolio with complementary antiviral opportunities alongside CimetrA®, supporting the Company's focus on immune modulation and inflammatory disease following the transition of CannEpil® to a partnered licensing model. Commercialisation of the Licensed Products will be run in tandem with the Company's commercialisation strategy for CimetrA®, given the complementary nature of the product profiles, with associated commercialisation costs shared across both programmes.

The transaction brings together defined commercialisation rights, access to Licensed Know-How and, and the purchase for US$1.00 of substantially all existing NutraVir inventory. These rights and inventory provide a foundation for Argent to commercialise the Licensed Products within the Territory.

NLC is entitled to cash sales milestone payments of US$100,000 at aggregate cumulative Net Sales of US$2.5 million and a further US$125,000 at US$5 million of Net Sales. Additionally, subject to shareholder approval, Argent shall also issue 2,000,000 Performance Rights to NLC, that vest at each Net Sales milestone and automatically convert into ordinary shares on a one-for-one basis. Argent will use commercially reasonable efforts to obtain the approvals within 120 days after execution. If approvals are not obtained, the parties will negotiate in good faith alternative consideration of substantially equivalent value in accordance with the agreement. The material terms of the agreement are set out in Schedule 1.

Strategic and Medical Rationale

The NLC portfolio is complementary to Argent's focus on immune modulation and anti-inflammatory development. NLC's scientific approach involves botanical compounds and research into viral processes, host pathways involved in viral entry and inflammatory responses.

Alongside CimetrA®, the portfolio broadens Argent's scientific perspective on the relationship between infection and the host inflammatory response. Under this Agreement, Argent's rights are limited to commercialisation of the Licensed Products. Any pharmaceutical development would require separate rights and applicable regulatory approvals.

Roby Zomer, Executive Chairman of Argent BioPharma, commented:

"This agreement is an important step in building Argent's next chapter. Following the CannEpil® licensing transaction, we are bringing greater focus to immune modulation and inflammatory disease, with CimetrA® at the centre of our development strategy. The NLC portfolio adds complementary antiviral opportunities and gives us a broader foundation from which to pursue commercial growth and long-term pharmaceutical value."

Jonathan Grunfeld, Vice President of Medical Development, commented:

"What excites us is the opportunity to bring NLC's antiviral science and immune modulation into a commercial strategy alongside Argent's immune-modulation expertise. Viral infection and the body's inflammatory response are closely linked and understanding both is central to tackling their impact on patients. Bringing the NLC portfolio alongside CimetrA® broadens our scientific perspective and strengthens our ambition to develop therapies that address important aspects of disease, from the infectious trigger to the host response. This is a compelling direction for Argent's medical development."

Licensed Portfolio and Intellectual Property

The agreement provides an exclusive, royalty-bearing licence to commercialise the antiviral applications identified in Schedule A, derived from specified patents, intellectual property and trade secrets associated with Tollovir (excluding NLCV-001), Tollovid and NutraVir.

The licensed scope excludes the Tollovir clinical-trial formulation designated NLCV-001, which contains a different concentration of Shikonin 95%.

The intellectual property schedule identifies:

- US Patent No. 11,857,517, titled "Compounds for Treating Coronavirus Infection", together with related applications in Israel and Europe;
- PCT Application PCT/IL2025/050199, published as WO2025/181810, titled "Botanical Antiviral Composition"; and
- trademark records associated with TOLLOVID, NLC-V, Todos Medical and NutraVir.

Argent's rights are limited to those expressly granted under the agreement. NLC retains all right, title and interest in the Licensed Products, the underlying intellectual property and know-how, and all Improvements pertaining to the Licensed Products. Dr. Arad has agreed only that know-how she owns which comprises a Licensed Product may be used by Argent under the agreement.

Argent BioPharma ltd
Suite 1, 295 Rokeby Road
Subiaco, WA 6008, Australia
+61 8 6555 2950
info@argentbiopharma.com

The licence territory is worldwide, excluding China. Exclusivity is subject to existing agreements involving TolloHealth LLC concerning Tollovid products in the United States. The Tollovid trade name is included for use outside the United States.

Argent also receives a 60-day right of first negotiation over new antiviral intellectual property developed or acquired by NLC or Dr. Arad during the agreement's term only where that intellectual property is derivative of or related to the Licensed Products. This right does not extend to non-antiviral applications, including inflammation, oncology, fibrosis, anti-ageing, neurodegenerative or metabolic applications.

Products and Commercialisation

The Licensed Products include Tollovid and NutraVir products and the Tollovir antiviral applications identified in Schedule A. NLCV-001 and other NLC products and development programmes are outside the licence unless expressly included in Schedule A.

NutraVir is presented as a dietary supplement. Its label states that it is not intended to diagnose, treat, cure or prevent disease. This supplement positioning is distinct from any future pharmaceutical development programme.

Research described in NLC's scientific materials provides a rationale for further evaluation of the portfolio. It does not establish clinical efficacy of the licensed formulations for treating viral infection or autoimmune disease. Patent grant likewise does not constitute regulatory approval or establish clinical safety or efficacy.

Any additional therapeutic development by Argent would require separate written rights from NLC, formulation-specific evidence and applicable regulatory approvals.

Commercial outlook

The agreement establishes a framework for commercialising the licensed portfolio. Outcomes will depend on funding, market access, product demand, applicable regulatory requirements and execution of the commercialisation plan. There is no assurance that the contractual sales milestones will be achieved or that pharmaceutical approvals will be obtained.

—Ends—

Authorised for release by the board of directors, for further information please contact:

Argent BioPharma
Roby Zomer
Chairman
+61 8 6555 2950
info@argentbiopharma.com

Argent BioPharma
Rowan Harland
Company Secretary
+61 8 6555 2950
info@argentbiopharma.com

About Argent BioPharma

Argent BioPharma Ltd. (ASX: RGT) is a revenue-generating specialty biopharmaceutical company focused on building a differentiated immune-modulation intellectual property platform through the development, commercialisation and strategic licensing of innovative therapeutics. The Company's portfolio is anchored by CimetrA®, a first-in-class immune-modulating platform targeting inflammatory and autoimmune diseases, supported by proprietary NanoBodies™ and peptide technologies, advanced nano-delivery systems and EU-GMP manufacturing capabilities. Following the global licensing of CannEpil®, Argent BioPharma has adopted a capital-efficient strategy that combines proprietary intellectual property, commercial-stage products, strategic licensing, manufacturing services and recurring royalty income to create long-term shareholder value. With a focused pipeline of immune-modulating technologies, a growing portfolio of proprietary pharmaceutical assets and an expanding commercial platform, Argent BioPharma is positioning itself as a next-generation specialty pharmaceutical company with a clear pathway toward expansion into the United States capital markets.

About NLC Ltd

NLC Pharma is an Israeli biotechnology company founded by scientist and inventor Dr. Dorit Arad. The company develops mechanism-based technologies and products from its work in viral proteases, natural bioactive compounds and proprietary drug-design methods. NLC's broader portfolio includes proprietary 1,4-naphthoquinone chemistry and a granted U.S. composition-of-matter patent covering phospholipid-containing formulations, alongside separate pharmaceutical-development programs. Except to the extent expressly identified in Schedule A, those broader assets and separate programs are not licensed under the agreement.

Argent BioPharma ltd
Suite 1, 295 Rokeby Road
Subiaco, WA 6008, Australia

+61 8 6555 2950

info@argentbiopharma.com

Schedule 1 - Material Terms

Term	Details
Monthly licence fee	US$15,000 per month from execution for 20 months. The fee is reviewed annually and may be increased, but not decreased, by mutual written agreement. Eligible patent-maintenance payments by Argent reduce royalties payable by Argent dollar-for-dollar.
First sales milestone	At US$2.5 million in aggregate cumulative Net Sales of Licensed Products: US$100,000; each of the 1,000,000 First Milestone Performance Rights, if issued following the required approval, vests and automatically converts into one ordinary share.
Second sales milestone	At US$5 million in aggregate cumulative Net Sales of Licensed Products: a further US$125,000; each of the 1,000,000 Second Milestone Performance Rights, if issued following the required approval, vests and automatically converts into one ordinary share.
Approvals	The issue of the 2,000,000 Performance Rights is subject to shareholder approval and applicable ASX Listing Rules. Argent will use commercially reasonable efforts to obtain approval within 120 days after execution. If approval is not obtained, the parties will negotiate in good faith alternative consideration of substantially equivalent value, which may include cash payable only when the relevant milestone is satisfied and under a mutually agreed payment schedule.
Tollovir royalties	12% on the first US$2.5 million of cumulative Tollovir Net Sales; 9% on the next US$2.5 million; and 6% thereafter.
Tollovid royalties	Separately, 12% on the first US$2.5 million of cumulative Tollovid Net Sales; 9% on the next US$2.5 million; and 6% thereafter.
NutraVir royalties	Separately, 12% on the first US$2.5 million of cumulative NutraVir Net Sales; 9% on the next US$2.5 million; and 6% thereafter.
Transaction expenses	Argent will reimburse NLC's pre-approved, reasonable and documented legal expenses in the amount of US$30,000 plus VAT.
Term	The agreement continues until August 2030, unless terminated earlier, and may be extended by written agreement.
Other	Net Sales is defined in the agreement by reference to gross invoiced sales, including relevant Affiliate sales, less specified permitted deductions. The sales milestones are contractual payment triggers and do not constitute revenue forecasts. Performance Rights expire five years after issue if the relevant milestone has not been achieved; unvested rights lapse if the agreement terminates earlier, and a change of control does not itself satisfy a milestone. The agreement also provides for a US$200,000 demand promissory note issued by NLC to C/M Master Fund, L.P. to be terminated and treated as satisfied upon execution.

Argent BioPharma ltd
Suite 1, 295 Rokeby Road
Subiaco, WA 6008, Australia
+61 8 6555 2950
info@argentbiopharma.com

	The agreement includes termination rights for specified payment, funding, business-plan, representation and confidentiality breaches, subject to applicable notice and cure provisions, and for bankruptcy events. Argent may also terminate on 60 days' notice in specified circumstances where it determines that a product is not commercially viable or that development costs following FDA discussions would not support a reasonable positive financial return. On termination, future budget funding and unaccrued licence fees cease, while accrued obligations remain payable. Licence rights terminate, subject to limited provisions concerning existing orders and inventory. Specified termination events also require transfer to NLC of product-related regulatory materials, data and other assets.

Argent BioPharma ltd
Suite 1, 295 Rokeby Road
Subiaco, WA 6008, Australia

+61 8 6555 2950

info@argentbiopharma.com